References
Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf 2005; 28: 763–88
Rude RK. Magnesium deficiency: a cause of heterogenous disease in humans. J Bone Miner Res 1998; 13: 749–58
Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS. 1998 Mar
Zaloga GP, Chernow B, Pock A, et al. Hypomagnesemia is a common complication of aminoglycoside therapy. Surg Gynecol Obstet 1984; 158: 561–5
Kuller L, Farrier N, Caggiula A, et al. Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1985; 122: 1045–59
British national formulary. No. 51. London: The Pharmaceutical Press, 2006 Mar
Evans TR, Harper CL, Beveridge IG, et al. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 1995; 31A: 174–8
Martin M, Diaz-Rubio E, Casado A, et al. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-in-duced hypomagnesemia: results of a controlled trial. Am J Clin Oncol 1992; 15: 348–51
Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin: a randomised trial. Br J Cancer 1986; 54: 19–23
Nguyen T, Steiner RW. A trial of oral magnesium supplementation in renal transplant recipients receiving cyclosporine. Transplant Proc 1998; 30: 4317–9
Rights and permissions
About this article
Cite this article
Drug-induced hypomagnesaemia: less of a problem than previously supposed?. Drugs Ther. Perspect 22, 18–21 (2006). https://doi.org/10.2165/00042310-200622060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200622060-00006